Penalty Amount
$96,000,000
New York Attorney General Letitia James and a bipartisan multistate coalition secured more than $96 million in settlements with generic drug manufacturers accused of conspiring to raise prices and limit competition. The settlement proceeds are being distributed to eligible consumers, and settling defendants agreed to cooperate in ongoing cases and make reforms to prevent future misconduct.
The manufacturers agreed to settlements totaling more than $96 million, with funds available as compensation to eligible consumers. Settling defendants also agreed to cooperate in ongoing multistate cases and make reforms intended to prevent future misconduct and ensure fair competition and compliance with antitrust laws.
This release concerns antitrust conduct rather than a privacy violation. In vendor, supplier, and distribution agreements, review competition-compliance representations, prohibitions on coordinating prices or bids, restrictions on exchanging competitively sensitive information, audit and cooperation rights, and termination rights for antitrust violations. Review customer and pricing agreements for provisions that could facilitate coordinated pricing or restrict independent competition, and ensure employee-facing policies and training address competitor interactions at industry events and through calls, email, and text messages.
Entity
Generic drug manufacturers, including Apotex, Heritage, Bausch, Lannett, and Glenmark Pharmaceuticals USA, Inc.
Industry
Healthcare"Attorney General James and the coalition have secured $96 million from Apotex and Heritage, Bausch and Lannett, and Glenmark Pharmaceuticals USA, Inc"
"have secured $96 million"
"compliance with antitrust laws."
"illegally colluded to raise prices"
"the defendants have agreed to cooperate in the ongoing multistate cases against the remaining corporate defendants and individual executives, as well as to make reforms to prevent future misconduct and ensure fair competition and compliance with antitrust laws."
$2.6M
New York and Connecticut reached a settlement with Boston Children’s Health Physicians and its IT security provider, XTIUM, after a 2024 breach exposed private information of approximately 825,000 New York residents and 62,871 Connecticut residents. The companies will pay $2.64 million and implement enhanced cybersecurity measures; additional penalties are conditional on violating the settlement.
New York Attorney General Letitia James joined 16 other attorneys general in urging Congress to pass proposed legislation addressing the federal government’s release of Jeffrey Epstein-related records. The press release says DOJ has not fully disclosed the records required by the original law and that personal information of at least 43 victims was exposed in released files; this is a legislative advocacy announcement, not an enforcement action imposing a penalty or remedy.
$1.9M
New York Attorney General Letitia James secured a settlement after an investigation found Dollar General stores routinely charged customers more than advertised or posted prices and issued confusing receipts. Dollar General must donate $1.875 million in food and personal items to Foodlink and implement pricing, receipt, training, and audit reforms.
New York Attorney General Letitia James released an updated guide warning voters that AI-generated election content and chatbots may provide misleading information. This is public guidance, not an enforcement action, and the release describes no penalty or privacy violation.
New York Attorney General Letitia James and a bipartisan coalition of 39 other attorneys general filed a motion in Character Technologies, Inc.’s bankruptcy, citing risks to children and sensitive user information and potential violations of state privacy laws. The coalition asks the court, the company, and any prospective buyer to require meaningful privacy and safety protections; no fine or final remedy is reported.
New York Attorney General Letitia James, the FTC, and six other state attorneys general asked a federal court to hold Martin Shkreli in contempt for allegedly trading pharmaceutical stocks and discussing pharmaceutical companies in violation of his lifetime industry ban. The requested sanctions include divestiture, an accounting of his trading, forfeiture of trading profits, and possible further fines or incarceration; the release describes a request to the court, not a new ruling imposing those measures.